Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of [<sup>111</sup>In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.

Molecular pharmaceutics·2026

Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026

Same author

Advances in Cancer Immunotherapy for Solid Tumors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Cancer immunology research·2026

Same author

Clonal determinants of organotropism and survival in metastatic uveal melanoma.

NPJ precision oncology·2026

Same author

Phenotypic and functional characterization of tumor-reactive T cells in malignant pleural effusions.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: May 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Immunotherapy for metastatic melanoma.

Christopher R Zito¹, Harriet M Kluger

¹Yale Cancer Center, Yale School of Medicine, 333 Cedar Street, New Haven, Connecticut 06451, USA.

Journal of Cellular Biochemistry

|October 19, 2011

Summary

Melanoma immunotherapy is advancing, with treatments like interleukin-2 and ipilimumab showing promise. This review explores new immune-enhancing strategies for melanoma treatment.

Area of Science:

Oncology
Immunology
Dermatology

Background:

Melanoma is recognized as an immunogenic tumor.
Interleukin-2 (IL-2) was the first cytokine approved for metastatic melanoma, yielding durable responses in some patients.
The development of immunotherapies offers hope for melanoma treatment.

Purpose of the Study:

To review recent advancements in melanoma treatment.
To discuss immune-enhancing approaches for melanoma.
To highlight novel therapeutic strategies in melanoma research.

Main Methods:

Review of current literature on melanoma immunotherapy.
Discussion of approved and investigational immune-enhancing treatments.
Analysis of recent advances in antitumor immunity for melanoma.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Experiment Videos

Last Updated: May 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Main Results:

Interleukin-2 (IL-2) has demonstrated efficacy in a subset of metastatic melanoma patients.
Ipilimumab, an antibody targeting CTLA-4, is a recently approved immunotherapy.
Several other promising investigational approaches are under active development.

Conclusions:

Immunotherapy represents a significant and evolving treatment modality for melanoma.
Advances in understanding tumor immunity are driving the development of new melanoma therapies.
Continued research into immune-enhancing strategies holds potential for improved melanoma patient outcomes.